Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development
If the efficacy readouts from SURMOUNT-1 are reproducible, Lilly almost certainly has a best-in-class medication this may be plainly reflected in the SURMOUNT-5 Phase 3b trial readout (1H 2025)
IGF-1 LR3 IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 , marketed online for muscle growth
Chaiyasate, The rise of ozempic face: analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists
In the ATTAIN-1 trial of orforglipron, the most common adverse events were nausea (2133% depending on dose), constipation (2129%), diarrhea (2123%), vomiting (1324%), and heartburn